Study record · Glutathione
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
No statistically significant difference in UPDRS change versus placebo.
Key result
No statistically significant difference in UPDRS change versus placebo.
Study details
Study designRandomized, double-blind, placebo-controlled pilot trial
PopulationPeople with Parkinson's disease whose motor symptoms were not adequately controlled
Sample size21
RouteIntravenous
Regimen / exposure1,400 mg three times weekly
Duration4 weeks + 8-week observation
ComparatorPlacebo
Primary endpoint / questionSafety/tolerability and preliminary UPDRS efficacy
Safety resultIV glutathione was reported as generally well tolerated in this small trial.
Key limitationsVery small disease-specific pilot; does not support general wellness or skin-lightening IV use.
Registry / identifierPMID 19230029